OKYO Pharma CEO Robert Dempsey Receives 15,000-Share Award

What Happened

• Robert (Robert John) Dempsey, CEO of OKYO Pharma Ltd (OKYO), received a grant/award of 15,000 shares on July 22, 2026. The reported acquisition price per share was $1.54, for a total reported value of $23,085. This was reported on an SEC Form 4 filed July 23, 2026.
• This transaction is an award/grant (code A) — an acquisition as part of compensation or a company grant — rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-22; reported on Form 4 filed 2026-07-23.
• Price per share: $1.54; total value reported: $23,085.
• Transaction type/code: A (award/grant/other acquisition).
• Shares owned after transaction: not specified in the provided filing.
• No 10b5-1 plan, tax-withholding, or cashless exercise noted in the provided details.
• Filing timeliness: filed the day after the transaction (no late-filing indication in the provided record).

Context

• Awards/grants are typically part of executive compensation (salary, incentive, or retention) and are different from open-market buys when interpreting insider sentiment. They do represent insider accumulation of equity but do not necessarily reflect a personal cash purchase decision.
• Retail investors should treat this as a compensation-related acquisition; combine with other filings and company news to assess insider conviction.